|
Randomized Study of Cognitive-Behavioral Therapy vs Imipramine and Their Combination for Panic Disorder Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified health advice, visits or treatment with a real mD. We are not doctors. Always consult your doctor about Randomized Study of Cognitive-Behavioral Therapy vs Imipramine and Their Combination for Panic Disorder conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Randomized Study of Cognitive-Behavioral Therapy vs Imipramine and Their Combination for Panic Disorder Clinical research trials and Randomized Study of Cognitive-Behavioral Therapy vs Imipramine and Their Combination for Panic Disorder healthcare trials happen in many of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new drugs. The purpose of the studies / projects is to solve particular human medical questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to discover cures for all varieties of conditions, such as Randomized Study of Cognitive-Behavioral Therapy vs Imipramine and Their Combination for Panic Disorder. Randomized Study of Cognitive-Behavioral Therapy vs Imipramine and Their Combination for Panic Disorder Clinical Trials and other clinical trials allow volunteers to have health treatment alternatives before they are available to the masses. Some times the human subjects obtain treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Randomized Study of Cognitive-Behavioral Therapy vs Imipramine and Their Combination for Panic Disorder clinical trial. Test subjects oftentimes receive the most effective healthcare possible for their Randomized Study of Cognitive-Behavioral Therapy vs Imipramine and Their Combination for Panic Disorder condition. Dangers are a reality, however, and may include extra or frequent physician visits, healthcare dangers (possibly life-jeopardising), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "R" Clinical Trials Conditions > Randomized Study of Cognitive-Behavioral Therapy vs Imipramine and Their Combination for Panic Disorder  Randomized Study of Cognitive-Behavioral Therapy vs Imipramine and Their Combination for Panic Disorder
Randomized Study of Cognitive-Behavioral Therapy vs Imipramine and Their Combination for Panic Disorder
For Condition: Panic Disorder
Status: Completed
Sponsor(s): National Institute of Mental Health (NIMH) , Long Island Jewish Medical Center
Synopsis: OBJECTIVES: I. Determine which treatment is most effective for patients with panic disorder: cognitive-behavioral therapy (CBT) plus imipramine (IMI), CBT plus placebo, CBT alone, IMI alone, or placebo alone.
Details: PROTOCOL OUTLINE: This is a randomized, double-blind, placebo-controlled study. Patients are randomized to receive one of five treatments: cognitive-behavioral therapy (CBT) alone, imipramine plus medical management (IMI), CBT plus IMI, pill placebo plus medical management (PLA), or CBT plus PLA. Patients are seen by therapists for 11 sessions over 12 weeks (3 sessions during days 1-10 followed by 6 weekly sessions and 2 biweekly sessions). Each CBT session lasts approximately 1 hour, each IMI session lasts approximately 30 minutes, and patients in combined treatment see 2 therapists for a total of about 80 minutes. Oral IMI or placebo is taken daily. Patients not responding to placebo or IMI after the initial 12 weeks are offered alternative treatment for up to 3 months or given a referral; responders continue to be treated monthly for the next 6 months. This is followed by a washout period of 6 months, after which patients receive final assessment. All therapy and assessment sessions are video- or audiotaped. Patients are interviewed by an independent evaluator at the start of treatment and 3, 9, and 15 months later, and must keep a set of weekly self-monitoring forms. In addition, patients complete rating forms and questionnaires, and undergo carbon dioxide measurement at the start of treatment and 3, 9, and 15 months later. At study conclusion, patients are told which medication they received and receive treatment recommendations.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Efficacy Study
Minimum Age/Maximum Age: 18 Years/64 Years
Genders: Both
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Principal diagnosis of panic disorder with or without mild agoraphobia, confirmed using the Anxiety Disorders Interview Schedule-Revised - At least one full or limited panic attack per week within 2 weeks prior to initial assessment and 2 weeks prior to treatment --Prior/Concurrent Therapy-- - Drug washout required if on anxiolytic or antidepressant medication No more than 10 benzodiazepine doses (0.5 mg alprazolam equivalent) within 2 weeks prior to treatment No more than 20 doses of benzodiazepine during baseline and acute treatment combined No more than one dose of benzodiazepine per day permitted - No concurrent competing treatment --Patient Characteristics-- - Not pregnant Negative serum pregnancy test required Effective contraception required of fertile women No psychotic, bipolar, or significant medical illnesses Not suicidal No significant substance abuse No prior nonresponse to either study treatment or related treatments No concurrent disability claims
Total Enrollment: 326
Location and Contact Information:
Overall Study Official:
JackGorman, Study Chair, Long Island Jewish Medical Center
Additional Information:
Study ID Numbers: 199/13462; LIJMC-5R10MH45963-07,BU-5R10MH45965,UPSOM-5R10MH45964,YALESM-5R10MH45966
Study Start Date: May 1998
Record last reviewed: July 1998
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00004834
Other Panic Disorder Studies:
1. Phase II Double-Blind, Placebo-Controlled Study of the Reinforcing Effects of Alprazolam in Patients with Anxiety
2. Pilot Study of Vestibular Rehabilitation Training for Panic Disorder With Vestibular Dysfunction
3. Randomized Study of Cognitive-Behavioral Therapy vs Imipramine and Their Combination for Panic Disorder
4. Interactive Computer Treatment for Panic Disorder
5. Panic Disorder Study
Related Studies:
Other Panic Disorder Clinical Trials
Other Clinical Trials
Other Clinical Trials
Randomized Study of Cognitive-Behavioral Therapy vs Imipramine and Their Combination for Panic Disorder
|
|
|
|
|
|
|
|
